Phase 3 Recruiting NIH
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrin…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05256225
Sites in Kentucky: - Saint Elizabeth Healthcare Edgewood — Edgewood, Kentucky
- Baptist Health Lexington — Lexington, Kentucky
- Baptist Health Louisville — Louisville, Kentucky
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Kentucky: - Saint Joseph Hospital East — Lexington, Kentucky
- University of Kentucky/Markey Cancer Center — Lexington, Kentucky
- Mercy Health - Paducah Cancer Center — Paducah, Kentucky
Phase 2 Recruiting NIH
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite tre…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554328
Sites in Kentucky: - University of Kentucky/Markey Cancer Center — Lexington, Kentucky
Phase 2 Recruiting NIH
This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05112601
Sites in Kentucky: - The James Graham Brown Cancer Center at University of Louisville — Louisville, Kentucky
- UofL Health Medical Center Northeast — Louisville, Kentucky
Phase 2 Recruiting Network
This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/R…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05640999
Sites in Kentucky: - Norton Hospital Pavilion and Medical Campus — Louisville, Kentucky
- Norton Suburban Hospital and Medical Campus — Louisville, Kentucky
Phase 1, Phase 2 Recruiting Industry
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor …
Sponsor: Eisai Inc.
NCT ID: NCT04300556
Sites in Kentucky: - Norton Healthcare — Louisville, Kentucky
Phase 1, Phase 2 Recruiting Industry
This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors
Sponsor: AstraZeneca
NCT ID: NCT05797168
Sites in Kentucky: - Research Site — Louisville, Kentucky
Phase 2 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.
Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT06481592
Sites in Kentucky: - UofL Health - Brown Cancer Center — Louisville, Kentucky
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to evaluate TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in participants with advanced selected solid tumors, who have failed or are not eligible for standard of care. The main questions it aims to answe…
Sponsor: Portage Biotech
NCT ID: NCT04969315
Sites in Kentucky: - Norton Cancer Institute — Louisville, Kentucky
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Kentucky: - Norton Cancer Institute — Louisville, Kentucky
Phase 1 Recruiting Industry
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
Sponsor: SystImmune Inc.
NCT ID: NCT05983432
Sites in Kentucky: - Norton Cancer Institute — Louisville, Kentucky
Phase 1 Recruiting Industry
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumo…
Sponsor: NextCure, Inc.
NCT ID: NCT06774963
Sites in Kentucky: - St. Elizabeth Healthcare — Edgewood, Kentucky
Phase 1 Recruiting Industry
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
Sponsor: TORL Biotherapeutics, LLC
NCT ID: NCT05103683
Sites in Kentucky: - University of Kentucky Medical Center — Lexington, Kentucky
Recruiting Industry
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …
Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in Kentucky: - Baptist Corbin — Corbin, Kentucky
- Baptist Hardin — Elizabethtown, Kentucky
- Baptist Lexington — Lexington, Kentucky
- Baptist Paducah — Paducah, Kentucky
Recruiting Industry
The primary objective of this study is to develop and train the Elephas live tumor diagnostic platform and determine the ex-vivo accuracy of the Elephas Score using in-vivo RECIST 1.1 as the reference method
Sponsor: Elephas
NCT ID: NCT05520099
Sites in Kentucky: - University of Louisville James Graham Brown Cancer Center — Louisville, Kentucky
NA Recruiting Academic/Other
This study aims to estimate the recurrence-free survival rates in women with endometrial cancer treated with selective versus sentinel node surgical staging. This study will gather information to help determine the best way to evaluate lym…
Sponsor: Rachel Miller
NCT ID: NCT06677112
Sites in Kentucky: - University of Kentucky — Lexington, Kentucky